Targeting HER2 in the Management of Potentially Resectable Gastric Adenocarcinoma: what are Oncologists Waiting for?

References

• Université Saint-Joseph . Epidemiology of gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/epidemiology-of-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=6∼150&usage_type=default&display_rank=6
   Google Scholar
• Université Saint-Joseph . Clinical features, diagnosis, and staging of gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/clinical-features-diagnosis-and-staging-of-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=1∼150&usage_type=default&display_rank=1
   Google Scholar
• Xiong B-H , ChengY, MaL, ZhangC-Q. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest.32(6), 272–284 (2014).
   PubMed Web of Science ®Google Scholar
• l-Batran SE , HomannN, PauligkCet al. Perioperative therapy with FLOT vs ECF/ECX in locally advanced gastric adenocarcinoma.The ASCO Post. (2020). www.ascopost.com/News/59969
   Google Scholar
• Becker K , MuellerJD, SchulmacherCet al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer98(7), 1521–1530 (2003).
   PubMed Web of Science ®Google Scholar
• Bang Y-J , CutsemEV, FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Harris L , FritscheH, MennelRet al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Qu J , QuX. The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer Biomark.17(1), 49–54 (2016).
   PubMed Web of Science ®Google Scholar
• Marx AH , TharunL, MuthJet al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol.40(6), 769–777 (2009).
   PubMed Web of Science ®Google Scholar
• Orlova R , BeliakNP, KutukovaSet al. Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy. J. Clin. Oncol.38(Suppl. 15), e16529–e16529 (2020).
   Web of Science ®Google Scholar
• Tong G , LiS, LinLet al. Trastuzumab with FLOT regimen for the perioperative treatment of resectable HER2 + advanced gastric cancer: a retrospective study. Cancer Manag. Res.12, 2481–2489 (2020).
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche . An open-label, multi-center study to evaluate the disease free survival rate of a perioperative combination of capecitabine (xeloda), trastuzumab (herceptin) and oxaliplatin (XELOX-trastuzumab) in patients with resectable gastric or gastro-esophageal junction adenocarcinoma. (2015). https://clinicaltrials.gov/ct2/show/study/NCT01130337
   Google Scholar
• Yamashita-Kashima Y , IijimaS, YorozuKet al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res.17(15), 5060–5070 (2011).
   PubMed Web of Science ®Google Scholar
• Hofheinz RD , HaagGM, EttrichTJ, BorchertK, KretzschmarA, TeschendorfC. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized Phase II trial of the AIO. J. Clin. Oncol. 38(Suppl. 15), 4502–4502 (2020).
   Web of Science ®Google Scholar
• Wagner AD , GrabschHI, MauerMet al. EORTC-1203-GITCG - the “INNOVATION”-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized Phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer19(1), 494 (2019).
   PubMedGoogle Scholar
• Kataoka K , TokunagaM, MizusawaJet al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger study). Jpn J. Clin. Oncol.45(11), 1082–1086 (2015).
   PubMed Web of Science ®Google Scholar
• Wang J , SaukelGW, GarberoglioCA, SrikurejaW, HsuehC-T. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J. Hematol. Oncol.3(1), 31 (2010).
   PubMedGoogle Scholar
• Okubo S , TakahashiT, MiyazakiYet al. [A case of unresectable local recurrence of gastric cancer successfully resected after pre-operative chemotherapy with trastuzumab]. Gan To Kagaku Ryoho42(12), 2094–2096 (2015).
   PubMedGoogle Scholar
• Nishino M , HosodaY, OkanoMet al. [A case of HER2-positive advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy with S-1/CDDP/trastuzumab]. Gan To Kagaku Ryoho42(12), 2043–2045 (2015).
   PubMedGoogle Scholar
• Kanaya N , ArataT, TanakayaK, YamasakiR, AokiH, TakeuchiH. [A case of HER2-positive esophagogastric junction cancer treated by using a neoadjuvant chemotherapy regimen consisting of trastuzumab]. Gan To Kagaku Ryoho41(12), 2285–2286 (2014).
   PubMedGoogle Scholar
• Wakabayashi Y , OkunoA, TogawaA. [Complete response with neoadjuvant chemotherapy and curative resection in a case of locally advanced gastric cancer that was strongly positive for HER2 with multiple liver metastases]. Gan To Kagaku Ryoho47(4), 621–624 (2020).
   PubMedGoogle Scholar
• Dong C-X . Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J. Gastroenterol.20(34), 12355 (2014).
   PubMed Web of Science ®Google Scholar
• Tevaarwerk AJ , KolesarJM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin. Ther.31(Pt 2), 2332–2348 (2009).
   PubMedGoogle Scholar
• Wainberg ZA , AnghelA, DesaiAJet al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res.16(5), 1509–1519 (2010).
   PubMed Web of Science ®Google Scholar
• Hecht JR , BangY-J, QinSKet al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – a randomized Phase III trial. J. Clin. Oncol.34(5), 443–451 (2015).
   PubMed Web of Science ®Google Scholar
• Phase II study of neoadjuvant XELOX + lapatinib in HER2(+) gastric cancer patients with liver metastasis – tabular view. (2020). https://clinicaltrials.gov/ct2/show/record/NCT02015169
   Google Scholar
• Smyth EC , RowleyS, CaffertyFHet al. Safety and efficacy of the addition of lapatinib to perioperative chemotherapy for resectable HER2-positive gastroesophageal adenocarcinoma: a randomized Phase 2 clinical trial. JAMA Oncol.5(8), 1181–1187 (2019).
   PubMed Web of Science ®Google Scholar
• Foukakis T , LundellL, GubanskiM, LindPA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol. Stockh. Swed.46(3), 277–285 (2007).
   PubMed Web of Science ®Google Scholar
• Magalhães H , Fontes-SousaM, MachadoM. Immunotherapy in advanced gastric cancer: an overview of the emerging strategies. Can. J. Gastroenterol. Hepatol.2018, 1–8 (2018).
   Web of Science ®Google Scholar